Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA approves J&J's Tremfya for psoriasis

July 14, 2017 7:11 PM UTC

FDA approved Tremfya guselkumab (CNTO 1959) from Johnson & Johnson (NYSE:JNJ) to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Spokesperson Brian Kenney told BioCentury that J&J expects to launch Tremfya within 2 weeks at an annual wholesale acquisition cost (WAC) of $58,100.

Tremfya is a human HuCAL mAb targeting the p19 subunit of IL-23...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Johnson & Johnson

MorphoSys AG

BCIQ Target Profiles

Interleukin-23 (IL-23)